2019冠状病毒病mRNA疫苗接种后的眼部不良事件:基于大型数据库的匹配队列与自控病例系列研究
该研究利用日本某大型城市医疗索赔与疫苗接种数据库,采用匹配队列和自控病例系列(SCCS)两种设计,评估BNT162b2 mRNA疫苗接种后葡萄膜炎、巩膜炎、视网膜静脉阻塞(RVO)和视神经炎复合结局的风险。匹配队列显示第二剂后84天内累积发病率差异为51.3事件/10万人(95%CI 16.2-84.3),但SCCS分析第一剂和第二剂的发病率比(IRR)均为0.89(95%CI分别为0.62-1.28和0.71-1.11)。作者认为,鉴于SCCS可消除时间不变混杂因素,当前结果提示COVID-19疫苗接种不太可能因果性增加眼部不良事件风险。
要点
- 匹配队列中第二剂后84天内疫苗接种组与对照组分别发生79和28例事件,累积发病率差异为51.3事件/10万人(95%CI 16.2-84.3)。
- SCCS分析显示第一剂和第二剂接种后风险期IRR均为0.89(95%CI分别为0.62-1.28和0.71-1.11)。
- 作者结论认为COVID-19疫苗接种不太可能因果性增加眼部不良事件风险,因SCCS可消除时间不变混杂因素。
核心结论
- 匹配队列分析发现第二剂接种后复合结局风险增加,但SCCS分析未显示风险增加。
- 作者认为,鉴于SCCS可消除时间不变混杂因素,当前结果提示COVID-19疫苗接种不太可能因果性增加眼部不良事件风险。
研究设计与样本
- 匹配队列与自控病例系列(SCCS)研究,数据来自日本某大型城市基于人群的医疗索赔和疫苗接种记录数据库。
- 匹配队列中,2021年2月至2021年9月接种BNT162b2疫苗者与未接种者按时间、出生日期、性别、Charlson合并症指数和健康保险入保期进行1:1匹配。
- SCCS分析纳入发生眼部不良事件的个体,采用条件泊松回归估计风险期(第一剂后0-21天和第二剂后0-84天)相对于剩余时期的发病率比(IRR)。
- 主要结局为葡萄膜炎、巩膜炎、视网膜静脉阻塞(RVO)和视神经炎的复合结局。
主要发现
- 第一剂后21天内,匹配队列共99 718对(平均年龄69.3岁,男性44%),疫苗接种组和对照组分别发生29和21例事件。
- 第二剂后84天内,疫苗接种组和对照组分别发生79和28例事件。
- 第一剂和第二剂的累积发病率差异(以对照组为参照)分别为2.9事件/10万人(95%CI -14.5至19.1)和51.3事件/10万人(95%CI 16.2-84.3)。
- SCCS分析显示第一剂和第二剂的IRR分别为0.89(95%CI 0.62-1.28)和0.89(95%CI 0.71-1.11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the risk of ocular adverse events after Coronavirus Disease 2019 (COVID-19) mRNA vaccination. DESIGN: Matched cohort and self-controlled case series (SCCS) studies. PARTICIPANTS: We used a population-based database of medical claims and vaccination records in a large Japanese city. In the matched cohort study, we identified individuals who received COVID-19 vaccination (BNT162b2) from February 2021 to September 2021. One control was selected from nonvaccinated individuals by matching time, date of birth, sex, Charlson comorbidity index, and the enrollment period for health insurance. In the SCCS study, we analyzed individuals who developed ocular adverse events. METHODS: In the matched cohort study, we applied the Kaplan-Meier estimator to estimate the cumulative incidence of ocular adverse events over 21 days after the first dose and 84 days after the second dose. In the SCCS method, we used conditional Poisson regression to estimate the incidence rate ratio (IRR) of ocular adverse events during the risk periods (0-21 days after the first dose and 0-84 days after the second dose) compared with the remaining periods. MAIN OUTCOME MEASURES: Composite outcome of uveitis, scleritis, retinal vein occlusion (RVO), and optic neuritis. RESULTS: There were 99 718 pairs eligible for the matched cohort study after the first dose (mean age, 69.3 years; male, 44%). The vaccinated and control groups developed 29 and 21 events, respectively, over 21 days after the first dose, and 79 and 28 events, respectively, over 84 days after the second dose. The differences in cumulative incidence (reference, the control group) were 2.9 (95% confidence interval, -14.5 to 19.1) events/100 000 persons and 51.3 (16.2-84.3) events/100 000 persons, respectively, for the first and second doses. The SCCS study showed the IRRs of 0.89 (0.62-1.28) and 0.89 (0.71-1.11) for the first and second doses, respectively. CONCLUSIONS: The matched cohort analysis found an increased risk for the composite outcome after the second dose; however, the SCCS analysis showed no increased risk. Considering that the SCCS can cancel out time-invariant confounders, the current results suggest that COVID-19 vaccination is unlikely to causally increase the risk of ocular adverse events. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Hashimoto Y, Yamana H, Iwagami M, et al. Ocular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination: Matched Cohort and Self-Controlled Case Series Studies Using a Large Database. Ophthalmology. 2022. PMID: 36306975. doi:10.1016/j.ophtha.2022.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。